Search
Cyclophosphamide Treatment Options
A collection of 2180 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
661 - 672 of 2180
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Dendritic Cell Vaccination in Patients With Advanced Melanoma
Completed
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Melanoma
Vaccination of Triple Negative Breast Cancer Patients
Completed
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine plus standard neoadjuvant chemotherapy and surgery to standard neoadjuvant chemotherapy and surgery alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas +1 locations
Conditions: Breast Neoplasms, Triple Negative Breast Cancer
Vaccination of High Risk Breast Cancer Patients
Completed
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor (ER)-positive, HER2-negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas +1 locations
Conditions: Breast Neoplasms, Breast Cancer
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Active Not Recruiting
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/04/2024
Locations: Beth Isreal Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Chronic Lymphocytic Leukemia
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
Recruiting
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
11/01/2024
Locations: University of Rochester, Rochester, New York
Conditions: DLBCL, Lymphoma, B-Cell
Auto Stem Cell Transplant for Lymphoma Patients
Recruiting
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Gender:
ALL
Ages:
75 years and below
Trial Updated:
11/01/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin as upfront window therapy (first-line therapy) works in treating patients with newly diagnosed intermediate-risk or high-risk rhabdomyosarcoma.
Gender:
ALL
Ages:
50 years and below
Trial Updated:
11/01/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Sarcoma
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Recruiting
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
Completed
RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy.
PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/31/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer, Nausea and Vomiting
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Terminated
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: The Oncology Institute of Hope and Innovation, Tucson, Arizona +140 locations
Conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Rapid Administration Pilot for Infusing Dinutuximab
Suspended
Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
10/30/2024
Locations: Childrens Hospital Los Angeles, Los Angeles, California
Conditions: Neuroblastoma
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
661 - 672 of 2180